1MBBS (G.R. Medical College, Gwalior, MP)
2MBBS M.G.M. Medical College, Indore, MP
3Senior Scientific Advisor, Editor-in-Chief and Chairman-in (ICOHAP-EM-2018)
*Corresponding Author Dr. Mayadhar Barik Senior Scientific Advisor, Editor-in-Chief and Chairman-in (ICOHAP-EM-2018) E-mail: mayadharbarik@gmail.com
Online published on 6 September, 2018.
The Prostate-specific antigen (PSA) is a serine protease (SP) and produced through the epithelial prostatic cells (EPCs). The major function is to liquefy seminal coagulum (LSC). The PSA is an extreme biomarker for the diagnosis and screeningtool for the prostate cancer (PC) as the first cancer biomarker approved by the FDA.
The quantity and serum isoforms of male PSA has been measured and distinguishing between suspicious, proven carcinoma, and benign inflammatory disease (BID) of the prostate. PSA was produced through the prostate, and this protein was expressed exclusively in Human subject.
A total of (98%/150) we observed that PSA protein expressed through the multiple non-prostatic tissues (MNPTs) in human subject. PSA expression, proteinfunction ismore likelyrelated to breast (95%), colon cancer (90% and prostate cancer 98%) respectively.
The PSA capable and advanced in molecular level study, with relevant clinical implications among human subject strictly count as a possible biomarker for early detection, diagnosis and prognosis and future research in different types ofcancers as well.
Prostate-specific antigen (PSA), epithelial prostatic cells (EPCs), breast, prostate
